Study suggests RFA could be first-line treatment for early-stage HCC patients
Published date : 03 January 2012
Article date : 03 January 2012
A study published in The American Journal of Gastroenterology suggests that radiofrequency ablation (RFA) might be a first-line treatment for selected patients with early-stage Hepatocellular Carcinoma.
The report from Japan found that one in four patients with hepatocellular carcinoma treated with percutaneous radiofrequency ablation was still alive ten years later.
Dr Shuichiro Shiina and colleagues at the Graduate School of Medicine of the University of Tokyo concluded that "RFA could be locally curative, resulting in survival for as long as 10 years, and was a safe procedure. RFA might be a first-line treatment for selected patients with early-stage HCC."
The study looked at the Cool-tip ablation system manufactured by Covidien.
The full report can be found here
Find out more about the Cool-tip ablation system here